Over the last several months, the American Society of Clinical Oncology published a number of guidelines related to the use of PARP inhibitors among those with BRCA-associated cancers, including guidelines focused on ovarian cancer,1 metastatic pancreatic cancer,2 and breast cancer.3 Additionally, costs of drugs also have great potential to influence policy, highlighting the importance of studies that suggest cost effectiveness when using PARP inhibitors to treat BRCA-associated pancreatic4 and ovarian cancer.5
1Tew, et al. J Clin Oncol. 2020 Oct. PMID: 32790492. 2Sohal, et al. J Clin Oncol. 2020 Aug. PMID: 32755482. 3Tung, et al. J Clin Oncol. 2020 Jun. PMID: 32243226. 4Wu, et al. J Natl Compr Canc Netw. 2020 Nov. PMID: 33152708. 5Muston, et al. Gynecol Oncol. 2020 Nov. PMID: 32951894.